Piramal PharmaNSE:PPLPHARMA -4.06%52 Days Payable is 214.29 as of Mar. 2026, which is 40% above its 10-year median of 152.95. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 52/100 and a GF Value™ of ₹174.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Piramal Pharma ranks better than 87.2% on this metric.
The historical rank and industry rank for Piramal Pharma's Days Payable or its related term are showing as below:
NSE:PPLPHARMA'
s Days Payable Range Over the Past 10 Years
Min: 109.66 Med: 152.95 Max: 219.44
Current: 219.44
During the past 6 years, Piramal Pharma's highest Days Payable was 219.44. The lowest was 109.66. And the median was 152.95.
NSE:PPLPHARMA's Days Payable is ranked better than 87.2% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs NSE:PPLPHARMA: 219.44
Piramal Pharma's Days Payable
increased
from Mar. 2025 (146.55) to Mar. 2026 (214.29).
It may suggest that Piramal Pharmadelayed paying its suppliers.
Piramal Pharma Days Payable Related Terms
Piramal Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:PPLPHARMA vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Piramal Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a Days Payable of 214.29 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Piramal Pharma and its competitors. This is 40% above median its historical median of 152.95. Over the past decade, Piramal Pharma's Days Payable has ranged from 109.66 to 219.44. According to the industry distribution chart, Piramal Pharma ranks #118 out of 922 companies in the Drug Manufacturers industry, placing it in the top 12.8%.
Is Piramal Pharma's Days Payable too high?
Piramal Pharma's current Days Payable of 214.29 is 40% above median its 10-year median of 152.95. Over the past 10 years, this metric has ranged from a low of 109.66 to a high of 219.44. The Drug Manufacturers industry median Days Payable is 90.61. Piramal Pharma's value of 214.29 is 136.5% above this industry median. Based on the distribution chart, Piramal Pharma ranks #118 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Piramal Pharma has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #118 out of 922 companies for Days Payable. This places Piramal Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.61. Piramal Pharma's value of 214.29 is 136.5% above this benchmark. Historically, Piramal Pharma's own Days Payable has ranged from 109.66 to 219.44 over the past decade. While the company's 10-year median is 152.95 vs. the industry median of 90.61, Piramal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current Days Payable of 214.29 is 136.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current Days Payable is 214.29, which is 40% above median its own 10-year median of 152.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹174.31, compared to a current price of ₹168.11 — trading 3.6% below its estimated fair value. The current Days Payable is 214.29, which is 40% above median its 10-year median of 152.95 and 136.5% above the Drug Manufacturers industry median of 90.61. Piramal Pharma's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Days Payable is 214.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued.
The current stock price of ₹168.11 is trading 3.6% below its estimated GF Value™ of ₹174.31.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
Days Payable: 214.29 (40% above median its 10-year median of 152.95)
GF Value™: ₹174.31 vs. price of ₹168.11 (3.6% below fair value)
Industry Position: 136.5% above the Drug Manufacturers median (#118 of 922)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
52GF Score
Get the complete analysis for NSE:PPLPHARMA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
